APAF1, encoding the protein apoptosis protease activating factor 1 (Apaf-1), has recently been established as a chromosome 12 gene conferring predisposition to major depression in humans. The molecular phenotypes of Apaf-1 variants were determined by in vitro reconstruction of the apoptosome complex in which Apaf-1 activates caspase 9 and thus initiates a cascade of proteolytic events leading to apoptotic destruction of the cell. Cellular phenotypes were measured using a yeast heterologous expression assay in which human Apaf-1 and other proteins necessary to constitute a functional apoptotic pathway were overexpressed. Apaf-1 variants encoded by APAF1 alleles that segregate with major depression in families linked to chromosome 12 shared a common gain-of-function phenotype in both assay systems. In contrast, other Apaf-1 variants showed neutral or loss-of-function phenotypes. The depression-associated alleles thus have a common phenotype that is distinct from that of non-associated variants. This result suggests an etiologic role for enhanced apoptosis in major depression.
Introduction
Depressive disorders including major depression (MDD) are serious, disabling illnesses. Approximately one in six individuals will be affected by a mood disorder in his or her lifetime. The World Health Organization estimates that MDD is the fourth most important cause worldwide of loss in disabilityadjusted life years, and will be the second most important cause by 2020. Including comorbidities, MDD may already be responsible for the largest worldwide loss of disability-adjusted life years. Linkage genetics can identify genes involved in MDD and the phenotypes of MDD-associated genetic variants can generate novel hypotheses for MDD therapy. Previously, we reported results of a genome-wide scan of large, high-risk MDD pedigrees from Utah. Highly significant linkage to MDD in males (HLOD ¼ 6.1) was observed at chromosome 12q22-q23.2. 1 We subsequently screened this 7.0 Mb region and found that the MDD-linked gene is APAF1, which encodes the protein apoptosis protease activating factor 1 (Apaf-1) (Abkevich et al., submitted for publication). Thus, APAF1 has been identified by positional cloning as a predisposition gene for MDD.
Apaf-1 is a 142 kDa protein that has a central role in the intrinsic apoptosis pathway. 2 Under most conditions, Apaf-1 is a monomeric cytosolic protein that is not active in apoptosis. Certain apoptotic stimuli lead to mitochondrion permeabilization and the release of cytochrome c. Cytochrome c binding is necessary for a conformational change in Apaf-1, which then oligomerizes into a wheel-like structure known as the apoptosome. 3 The apoptosome recruits procaspase 9 and induces its autocatalytic cleavage. Activated caspase 9 initiates the cascade of events leading to destruction of cellular components, which is a hallmark of apoptosis. 4, 5 While its role in apoptosis is well established, other functions of Apaf-1 have not been clearly identified.
Apaf-1 alleles observed to segregate with MDD are found in one of two regions of the protein: a region containing WD repeats (E777K, N782T) or an uncharacterized linker region (C450W, Q465R). However, it was not clear from their location how these variants might affect Apaf-1 function. They could enhance or diminish apoptosome function or assembly via modulation of intra-or inter-molecular interactions of Apaf-1. Additionally, it was possible that the variants altered some as yet unknown function of Apaf-1. We chose to focus on the known function of this protein in apoptosome-dependent apoptosis. The phenotype of the variants was investigated in two systems: an apoptosome reconstitution assay using purified proteins that assemble and activate procaspase 9, 5 and a yeast cell death assay in which expression of human proteins via transformation forms a functional apoptosis pathway. 6 The four MDD-linked Apaf-1 alleles share a common gain-of-function phenotype in both assays. In addition, other naturally occurring Apaf-1 variants that have not been observed to segregate with MDD (Abkevich et al., submitted for publication) were tested in the same assays. The variants that do not segregate with MDD (with one exception) have either neutral or loss-of-function (partial or total) phenotypes. These results indicate that aberrant increase of apoptosis is an etiologic factor for MDD in a subgroup of patients carrying specific alleles of APAF1. Several prior lines of evidence suggested that increased apoptosis (or the converse, decreased neurogenesis) might be more generally observed in MDD patients than in euthymic individuals. [7] [8] [9] [10] [11] However, all of the prior results could be explained if changes in neuronal apoptosis or neurogenesis are secondary effects of a depressive state. Our results demonstrate that modulation of apoptosis may have a causative role for MDD in humans.
Materials and methods

Apaf-1 and variants thereof
Full-length APAF1 was cloned from a cDNA library (Clontech, Palo Alto, CA, USA) using primers containing BamHI and XhoI sites at the 5 0 and 3 0 ends.
Primer A1: GATGGATCCAGCCACCATGGATGCAA AAGCTCGAAATTG Primer A2: CAGCAATTGACTTGCTCTGAGTGC Primer A3: CTATTACTCGAGTTCTAAAGTCTGTA AAATATATAAAATACC Primer A4: AGAGAAACTTCTAGAAATCAAGGC It was necessary to amplify the gene in two pieces (using primers A1 þ A2, and A3 þ A4), which were subsequently ligated using the internal EcoRI site at base 2630 in NM_181861. The resultant APAF1 was cloned into the BamHI and XhoI sites of the BlueScript KS vector (Stratagene, La Jolla, CA, USA) and the insert sequence was confirmed to encode the full-length 1248 amino-acid Apaf-1 protein. The fulllength coding sequence of Apaf-1 (minus the stop codon) was excised from the BlueScript KS vector with BamHI and XhoI and ligated into BamHI, NotIdigested pFastBac1 along with a synthetic fragment with XhoI and NotI cohesive ends (TCGAG(CAC) 9 -TAATGAGC, GGCCGCTCATTA(GTG) 9 C). The resultant clone contained the DNA coding for the fulllength 1248 residue wt Apaf-1 sequence with an 11 residue C-terminal extension (ÀLE(H) 9 ). Mutations in Apaf-1 cDNA were generated by site-directed mutagenesis using the QuikChange XL-Site-Directed Mutagenesis kit (Strategene, La Jolla, CA, USA) following the manufacturer's direction. Each APAF1 allele was subcloned into the NotI/KpnI sites of the baculovirus pFastBacI expression vector (Life Technologies, Inc.). All vectors were sequenced to ensure expression of the correct variants.
The expression plasmids were transformed into MAX efficiency DH10Bac competent Escherichia coli cells (Life Technologies, Inc.). The recombinant viral DNA bacmids were then purified and transfected into Sf21 insect cells according to the Bac-to-Bac Baculovirus Expression procedure (Life Technologies, Inc.). All purified bacmids were confirmed by PCR prior to transfection. Expression was verified by immunoblot of the P1 virus. Expression-positive clones were selected and subjected to two rounds of selection, with the resultant P3 virus amplified for expression in Sf9 cells.
Expression was performed at 10 and 40-l scales in Wave Bioreactors (Wave Biotech). At a density of 2.2 Â 10 6 cells/ml, Sf9 cells growing in Sf900 media were infected with recombinant baculovirus at a multiplicity of infection of 2.0. Cells were harvested by centrifugation 48 h after infection and stored at À801C for subsequent purification.
Protein was purified according to a modification of a published method. 5 Cell paste corresponding to 5 l of Sf9 culture was resuspended in 10 ml buffer A (20 mM HEPES, pH 7.5, 10 mM KCl, 5 mM 2-mercaptoethanol, 1.5 mM MgCl 2 , 1 mM NaN 3 supplemented with 0.1 mM 4-(2-aminoethyl)benzenesulfonyl fluoride) for each 1 g cell paste. The resuspended cells were lysed by sonication using a Vibracell VC500 (Vibracell, Inc.), and the resultant lysate clarified by centrifugation at 10 000 g for 30 min. The clarified supernatant was mixed with 20 ml of Ni-affinity resin (ProBond, Invitrogen) and the resultant slurry allowed to flow by gravity through a 2.5 cm diameter EconoColumn (Bio-Rad Laboratories, Inc.). The retained resin was washed with 1 column volume (CV) of buffer A, followed by 300 CV of buffer A supplemented with 1 M NaCl and 20 mM imidazole. After a 1.5 CV wash with buffer A to remove the salt, protein was eluted with buffer A supplemented with 250 mM imidazole. The purified protein was dialyzed into buffer B (20 mM HEPES, pH 7.5, 10 mM KCl, 1.5 mM MgCl 2 , 1mM EDTA, 1 mM EGTA, 1 mM dithiothreitol, 1 mM NaN 3 ), flash frozen in aliquots and stored at À801C for subsequent use.
C1 and C2 was used to generate a subfragment containing a D315A mutation. PCR with primers C3 and C4 was used to generate a subfragment containing a C-terminal extension ÀLE(H) 9 .
The fragments were combined by overlap extension PCR with primers C1 and C4 and cloned into a BamHI/EcoRI-digested pFastBacI baculovirus expression vector and confirmed by DNA sequencing.
Primer C1: AGCTGGATCCTATAAATATGGACGAA GCGGATCGG Primer C2: GGGGTGGCAGCTGGCTCGGGGTTACT GCCA Primer C3: CCCGAGCCAGCTGCCACCCCGTTCCA GGAA Primer C4: AGCTGAATTCTCATTA(GTG) 9 TGATGT TTTAAAGAAAAGTTTTTTCC A R32S mutation found in all clones and in the parent plasmid was corrected using a QuikChange Mutagenesis kit as per the manufacturer's instructions. The final clone was confirmed by DNA sequence analysis. Recombinant virus for expression in Sf9 cells was generated as for Apaf-1 (see above). Expression was also as for Apaf-1, except that cells were harvested 22 h postinfection.
Protein was purified according to a modification of a published method. 5 Nickel affinity purification was carried out as outlined for Apaf-1 (see above). The resultant nickel column eluate was further purified by diluting 10-fold with buffer A and loaded on a 50 ml Q-Sepharose HiLoad column (GE Healthcare, Inc.) equilibrated with buffer B supplemented with 50 mM NaCl. After a 1 CV wash with buffer B plus 50 mM NaCl, the protein was eluted using a linear gradient of 50-300 mM NaCl in buffer B. The resultant purified protein was dialyzed into buffer B, flash frozen in aliquots and stored at À801C for subsequent use.
The D315A mutation present in our purified procaspase 9 eliminated the major activation cleavage site. This substantially prevented autocleavage of purified procaspase 9. Mass spectrometry of apoptosome reconstitution reactions revealed that cleavage of procaspase 9 (315A) occurred predominantly between residues 306 and 307, with additional cleavage of the C-terminal fragment between residues 330 and 331.
Apoptosome reconstitution
Apoptosome reconstitution experiments were carried out according to a modification of a published method. 5 Purified proteins were mixed together and diluted with buffer B to final concentrations of 1.7 mM procaspase 9 and 3.4 mM Apaf-1. This mixture was then supplemented with an additional 1 mM MgCl 2 , 1.7 mM cytochrome c (horse heart, Sigma Chemical Co.) and 0.1 mM dATP, and incubated at 301C. Conversion of procaspase 9 to caspase 9 was visualized by Coomassie stain (Simply Blue Stain, Invitrogen Corp.) following SDS-PAGE using 4-20% gradient gels (Bio-Rad Laboratories, Inc.). Immunoblots were probed using rabbit anti-caspase 9 polyclonal antibody (Chemicon) as the primary antibody, goat-anti rabbit IgG alkaline phosphatase conjugate (Bio-Rad Laboratories, Inc.), and developed using an alkaline phosphatase substrate (Bio-Rad Laboratories, Inc.) according to the manufacturer's instructions. Caspase 9 activity was measured colorimetrically using the Ac-LEHD-pNA substrate (Upstate Biotechnology) following the manufacturer's instructions. Substrate cleavage led to absorption at 405 nm. A microtiter plate reader (Molecular Dynamics, Inc.) was used to record absorption values. Paired t-tests were performed using Prism 4.02 for Windows (GraphPad Software).
For mass spectrometric studies, apoptosome reconstitution reactions were carried out as above, except that incubation was carried out at ambient temperature. LC-MS experiments were carried out on an Ultra-Plus II HPLC (Micro-Tech Scientific Inc) and mass spectrometry (MS) was performed on a Q-Tof I quadrupole-Tof mass spectrometer (Waters). An HTS-PAL autosampling robot (CTC Analytics AG) was utilized for automated sample injections. Mobile phases and HPLC conditions were as follows: Column -Jupiter 5 mm, 300 Å , 1Â 50 mm C4 column, #147659-2; solvent A was 0.10% TFA in 95% water, 5% acetonitrile; solvent B was 0.10% TFA 5% water, 95% acetonitrile; the flow rate was 95 ml/min, and the amount of sample per injection was 8 ml.
Yeast death reconstitution Apoptosis in yeast was reconstituted following a published method. 6 Expression plasmids were produced in E. coli DH5a. Sequences for each allele of APAF1 (1-541) were generated by PCR amplification using primers A1 (see above) and A5 (CTGTCTCGAG TTAACTGACTGCACAATCCTTTTCATC) from the corresponding full-length APAF1 in BlueScript KS. Sequences for each allele of APAF1 (full length) were obtained from the corresponding full-length APAF1 in BlueScript KS by BamHI and XhoI restriction digestion. Each APAF1 allele (full-length or 1-541) was subcloned into p416Gal1 12 between BamHI and XhoI sites that expresses an inserted gene under control of the GAL1 promoter and allows growth in uridine-free medium by expression of the URA3 gene. Human CASPN3 and CASPN9 were PCR amplified from MGC clones (accession numbers BC016926 and BC006463, ATCC) using the following primers with BamHI and EcoRI sites at the 5 0 and 3 0 end.
Primer C3 forward: GATGGATCCACCATGGAGAA CACTGAAAACTCAGTGG Primer C3 reverse: CGGAATTCTTAGTGATAAAA ATAGAGTTCTTTTGTGAGC Primer C9 forward: GATGGATCCGCCATGGACGA AGCGGATCGGC Primer C9 reverse: CGGAATTCTTATGATGTTTTA AAGAAAAGTTTTTTCCGG
Variants in Apaf-1 segregating with MDD promote apoptosis J Harlan et al CASPN3 was cloned into p413Gal1 12 that expresses an inserted gene under control of the GAL1 promoter and allows growth in histidine-free medium by expression of the HIS3 gene. CASPN9 was cloned into p415Gal1 12 that expresses an inserted gene under control of the GAL1 promoter and allows growth in leucine-free medium by expression of the LEU2 gene.
Yeast growth media and plates were made from reagents purchased from Bio101 following their protocols. W303a yeast was transformed with p413 Gal1-CASPN3, p415Gal1-CASPN9 and either p416 Gal1-APAF1 (wild type or variant) or the empty vector p416Gal1 using the lithium acetate method. 13 Transformants were picked and purified by two rounds of streaking on SC glucose plates lacking uridine, histidine and leucine. Individual yeast clones containing CASPN3, CASPN9 and APAF1 expression vectors were cultured in SC medium supplemented with 2% raffinose to log phase, serially diluted and spotted onto SC plates containing either 2% glucose, 2% galactose or 2% galactose with varying concentrations of glucose. The plates were incubated in a 301C incubator for 2-3 days and photographed.
Results
In vitro apoptosome reconstitution assays Functional reconstitution of apoptosome formation and procaspase 9 activation using purified recombinant procaspase 9, Apaf-1 and cytochrome c has been demonstrated. 5 In this study, dATP-dependent procaspase 9 (D315A) processing was monitored by electrophoretic separation of procaspase 9 from caspase 9, and the resultant caspase 9 activity by colorimetric measurement of cleavage of a modified caspase 9 peptide substrate (Ac-LEHD-pNA). To assess the phenotype of Apaf-1 variants, an equimolar amount of purified recombinant variant protein was substituted for wild-type Apaf-1, holding all other conditions of the apoptosome reconstitution assay the same.
Increased disappearance of procaspase 9 following incubation of apoptosome reconstruction mixtures is physical evidence that each of the four variants in Apaf-1 that cosegregate with depression (C450W, Q465R, E777K, N782T; Abkevich et al., submitted for publication) enhanced the biochemical function of Apaf-1 relative to wild-type (Figures 1a-c) . The identities of procaspase 9 and processed caspase 9 were confirmed by immunoblotting (Figure 1c) . The disappearance of procaspase 9 detected by SDS-PAGE separation and Coomassie blue staining was consistently higher for each of the four MDD-linked alleles than for wild-type Apaf-1, at several time points up to about 4 h (Figure 1a-c) . Procaspase 9 was usually undetectable in apoptosome mixtures containing any of the MDD-linked variant Apaf-1 proteins by about 4 h of incubation, whereas it was usually observed in apoptosome mixtures containing wild-type Apaf-1 through at least 4 h of incubation (Figure 1c ). Mass spectrometry confirmed that relative amount of remaining procaspase 9 after 120 min incubation was greater in an apoptosome reconstitution mixture containing wild-type Apaf-1 (12%) than in mixtures containing Apaf-1 C450W (11%), Q465R (8%), E777K (4%) or N782T (6%).
Measurement of caspase 9 activity, particularly at 2 and 4 h time points, provided enzymatic evidence that each of the four MDD-linked Apaf-1 alleles resulted in enhanced apoptosome activity in the reconstitution assay, relative to wild-type Apaf-1 ( Figure 2 ). The increase of caspase 9 activity for each of these alleles compared to wild-type Apaf-1 was assessed using a paired t-test across 34 experiments (incubation time range for reconstitution, 65-240 min). Figures 1a and b and measured by mass spectrometry. Caspase 9 activity peaked between 2 and 4 h regardless of the Apaf-1 allele included in apoptosome reconstruction mixtures, after which point it began to decline ( Figure 2) . The reason for the caspase 9 activity decline is not apparent, but it does not appear to be due to proteolytic cleavage of processed caspase 9, Apaf-1 or cytochrome c ( Figure  1c ). Caspase 9 activity was somewhat higher in mixtures containing any of the four MDD-linked variant Apaf-1 proteins after about 1 h incubation and after about 6 h incubation, but these differences were not as pronounced as those observed at intermediate time points (Figure 2) .
The level of caspase 9 activity increased more rapidly with Apaf-1 variants E777K and N782T than with the wild-type or variants C450W and Q465R (Figure 2) , as did the disappearance of procaspase 9 (Figures 1a, b) . The caspase 9 activity also started to decline sooner with these variants (Figure 2) . In reconstruction reactions containing variants C450W and Q465R, the time course resembled wild-type reactions in shape while the absolute levels of caspase 9 activity and procaspase 9 processing were higher. For each Apaf-1 allele, the level of caspase 9 activity roughly correlates with disappearance of procaspase 9 over several reconstitution time courses (compare the results shown in Figures 1c and 2 ). Such correlations were not apparent between Apaf-1 alleles, as time courses for increase and decrease in caspase 9 activity overlapped, rendering simple calculations of relative specific activities after complete processing of procaspase 9 unreliable.
Caspase 9 activity was also measured in apoptosome reconstruction mixtures containing Apaf-1 variants that have not been observed to segregate with MDD (Figure 2) . Most of these (K144T, S357L, Variants in Apaf-1 segregating with MDD promote apoptosis J Harlan et al L415P, D479E, E625A) were naturally occurring variants that were observed in the same Caucasian population in which the MDD linkage to APAF1 was established (Abkevich et al., submitted for publication). K144T was observed in a single control individual. S357L and L415P were each observed once in depressed males. D479E and E625A were each observed in both depressed and control individuals. None of these variants were observed in MDD pedigrees. One variant (T953A) was observed in a single affected male in an MDD pedigree but did not cosegregate with depression in that pedigree. T953A was not observed in any other individuals. One tested Apaf-1 variant (K160R) was described in the literature as a P-loop mutant that was unable to associate with Apaf-1 or procaspase 9, and acted as a dominant negative form.
14 It is uncertain whether this form occurs in nature. Among the Apaf-1 variants tested that did not cosegregate with MDD, none showed the same gain-of-function phenotype as C450W, Q465R, E777K and N782T ( Figure 2 , Table 1 ). L415P showed a complete loss-of-function phenotype even though equimolar protein was used in the assay mixture. E625A was essentially indistinguishable from wildtype Apaf-1. K144T, K160R, S357L, D479E and T953A each showed a partial loss-of-function, or hypomorphic, phenotype. An additional Apaf-1 variant, 437ter, that had been observed in a depressed male could not be tested in the apoptosome reconstruction assay because no stable protein could be purified.
Yeast death reconstitution assays
A functional apoptosis pathway can be reconstituted in yeast by overexpression of human Apaf-1, caspase In each panel, the rightmost lanes of both Coomassie blue-stained and immunoblotted panels show reactions to which no Apaf-1 was added. These lanes show that very little autocleavage of purified procaspase 9 occurred.
Variants in Apaf-1 segregating with MDD promote apoptosis J Harlan et al 9 and caspase 3 proteins. 6 To create an assay system with the ability to measure either loss-of-function or gain-of-function phenotypes for Apaf-1 variant proteins, the three human genes were transformed into yeast W303a in separate expression vectors utilizing the GAL1 promoter. Transformed yeast plated on media with galactose as the sole carbon source express the three proteins at high levels and thus die due to induced apoptosis rather than grow and form colonies. Conversely, when glucose is used as the sole carbon source with the same yeast, expression of the artificial apoptosis pathway is repressed and colonies form. Depending on the strength of a particular Apaf-1 variant to induce apoptosis, yeast phenotype will differ as the glucose:galactose ratio in the growth medium is varied. Gain-of-function Apaf-1 transformants do not require as high a level of Apaf-1 expression to induce apoptosis. Thus, no colonies are observed at higher levels of glucose in the galactose background. Neutral Apaf-1 transformants, by definition, grow indistinguishably from wild-type transformants. Partial loss-of-function transformants require higher levels of Apaf-1 expression to induce apoptosis. These transformants continue to form colonies at higher glucose:galactose ratios but do not form colonies at low ratios. Transformants with complete loss-of-function Apaf-1 variants grow on galactose plates in the absence of any glucose, as do cells transfected with an empty control vector.
The effect of Apaf-1 variants was initially measured in the yeast cell death assay using a vector expressing Apaf-1 truncated at residue 541. Since expressed protein does not contain the WD repeat regions, the wild-type version is constitutively active. [15] [16] [17] The two MDD-linked alleles that could be tested in this format (C450W, Q465R) both showed a gain-offunction phenotype (Figures 3a, b ; Table 1 ). In contrast, none of the tested Apaf-1 variants that did not cosegregate with MDD appeared to have a gain-offunction phenotype. K160R, L415P and 437ter transformants all grew on galactose medium, indicating complete loss of Apaf-1 function (Figure 3g ; Table 1 ). Positions are given for transcript NM_181861. The four variants that segregated with major depression in Utah males are listed first. Other variants were observed in a Utah population sample but were not observed to segregate with major depression The bold entries highlight the preponderance of 'Gain-of-function' among the MDD variants compared to the others.
Variants in Apaf-1 segregating with MDD promote apoptosis J Harlan et al S357L transformants were of the hypomorphic class ( Figure 3f ; Table 1 ), and D479E transformants were not distinguishable from wild type (Figure 3e ; Table 1 ). C-terminal variants (E625A, E777K, N782T, T953A) could not be tested in this system because the Apaf-1 protein was truncated at amino acid 541. A second yeast death reconstruction assay, which differed from the first assay by including a full-length Apaf-1 construct, was devised to enable testing of the C-terminal variants (Figures 3c, d ; Table 1 ). In this system, three of the MDD-linked Apaf-1 variants (Q465R, E777K, N782T) had a gain-of-function phenotype. Results for Apaf-1 variants S357L, L415P, 437ter and D479E were also similar to those obtained using the corresponding N-terminal Apaf-1 expression vectors. However, in contrast to the results in N-terminal expression experiment, C450W transformants showed a partial loss-of-function phenotype. Among the Apaf-1 variants that were tested only in the full-length construct, K144T and E625A were not distinguishable from wild-type Apaf-1, while T953A showed a gainof-function phenotype.
Discussion
Using large, high-risk MDD pedigrees from Utah, strong evidence of a depression-causing gene on chromosome 12 (HLOD ¼ 6.1) was discovered.
1 By conducting high-throughput resequencing to find alleles that cosegregated with MDD within the linkage region, APAF1 was identified as the MDD predisposition gene (Abkevich et al., submitted for publication). Apaf-1 variants have now been characterized for their effect on the known function of Apaf-1 in the intrinsic apoptosis pathway. In addition to the four MDDassociated variants, we determined the phenotypes of several Apaf-1 variants that had either been described in the literature 14 or discovered in the same population in which APAF1 linkage to MDD had been established but not within the MDD pedigrees showing linkage to chromosome 12 (Abkevich et al., submitted for publication). In two independent assay systems, MDD-linked Apaf-1 alleles shared a common gain-of-function apoptosis phenotype that was distinct from the phenotypes of other Apaf-1 variants. The observation of a common altered biochemical function for all known MDD-linked Apaf-1 alleles strongly suggests an etiologic role for increased apoptosis in MDD. Our work is complementary to a growing body of evidence associating increased neuronal apoptosis (or decreased neurogenesis) with MDD, but which until now lacked definitive evidence that increased apoptosis may be causative for, rather than a symptom of, MDD. [7] [8] [9] [10] [11] Replication and expansion of our results, particularly to include assessment of the phenotype of Apaf-1 variants in brain cells, will increase understanding of the connection between apoptosis and MDD.
The effect of these variants on Apaf-1 function was assessed with two different methods. In a first set of experiments, purified recombinant Apaf-1 protein (wild-type or variant) was mixed with procaspase 9, cytochrome c and dATP to reconstruct the apoptosome complex. These experiments addressed the molecular phenotypes of Apaf-1 variants, that is, how they affect the ability of Apaf-1 to process and thus activate caspase 9. In a second set of experiments, Apaf-1 protein (wild-type or variant) was expressed in yeast cells with procaspase 9 and procaspase 3 to constitute a functional human cell death pathway. These experiments revealed the cellular phenotypes of Apaf-1 variants by demonstrating differential effects of these variants to induce apoptosis. These distinct methods yielded highly consistent results for both MDD-linked and other Apaf-1 variants. Combining results of both assay systems, in nine of 10 sets of experiments, the four MDD-linked variants consistently increased Apaf-1 function (Table 1) . Conversely, in 17 of 19 sets of experiments variants that have not been observed to segregate with MDD consistently did not increase Apaf-1 function ( Table 1 ). All of the discrepant results were in the yeast cell death assay using full-length Apaf-1 expression constructs. In this system, the MDD-linked variant C450W showed a partial loss-offunction, rather than gain-of-function, phenotype. One variant (T953A) that was observed in a male MDD patient and never in controls, but did not cosegregate with MDD in any families studied to date, had a gain-of-function phenotype in this assay. Variant Apaf-1 D479E (which was detected in one male MDD patient and one control individual, and has not been observed to cosegregate with MDD) showed a neutral phenotype in the majority of experiments, but sometimes appeared to have a moderate gain-of-function phenotype. The methods used to establish the common phenotype of MDDlinked Apaf-1 alleles share two limitations. First, neither fully recapitulates the apoptotic process in a human cell (particularly a brain cell). Second, the experiments reported here provide no information to help understand the sex-specific nature of our linkage observation. These limitations do not affect the central conclusion of our work, that there is very strong and consistent evidence that MDD-linked Apaf-1 alleles share a common gain-of-function phenotype that is distinct from the phenotypes of other Apaf-1 variants.
The phenotypes of MDD-linked Apaf-1 alleles help define regions of the protein that may be important for its function. Several functional domains in Apaf-1 have been defined: 2, 5 an N-terminal caspase activating and recruiting domain (CARD, residues 1-89), a CED-4 homology region (residues 91-412) and two WD repeat regions, one comprised of seven WD repeats starting at residue 605, and one containing six WD repeats starting at residue 962. The CARD has two known functions; it is responsible for recruitment of procaspase 9 to the apoptosome through interaction with the similar CARD on procaspase 9, 2 and it forms the central structure of the hub of the wheel-like apoptosome complex. 3 The CED-4 homology region contains a nucleotide-binding motif and is part of a family of nucleotide-dependent oligomerization domains known to facilitate conformational changes and protein oligomerization upon nucleotide binding. 18 This region comprises part of the hub and spokes of the apoptosome. 3 Binding of dATP to the CED-4 homology region is one of two interactions necessary for monomeric Apaf-1 to form an active apoptosome 19 and is thought to make this region more rigid, extending the WD repeat regions away from the central hub. 3 None of the MDD-associated variants are in the CARD or CED-4 homology domain, and so are unlikely to directly affect interaction with caspase 9, homophilic interactions involved in apoptosome oligomerization or nucleotide binding.
Two of the MDD-linked variants (C450W, Q465R) are found in the region between the CED-4 homology region and the WD repeats. This portion of Apaf-1 is not strongly homologous to other proteins, and its function is not known, although from its structure it is likely that this portion of Apaf-1 forms much of the spokes of the apoptosome. Based on their location, these amino acids may have a role in facilitating the conformational change that occurs upon cytochrome c and nucleotide binding. This might occur either by destabilizing the closed monomeric form of Apaf-1, lowering the energy barrier of a transitional conformation, or stabilizing the open oligomeric apoptosome. Based on the recent 2.2 Å resolution crystal structure of the N-terminal portion of Apaf-1 (20) , amino acid 450 is at the junction between the winged helix domain and helical domain II; amino acid 465 is at the end of the first a helix in helical domain II. Changes in these positions could conceivably facilitate the proposed conformational change in which helical domain II moves away from other N-terminal domains of Apaf-1 following nucleotide hydrolysis (Figure 5c in Riedl et al. 20 ). We have conducted titration experiments, but neither C450W nor Q465R show any differential dependence on nucleotide concentration from wild-type Apaf-1 in apoptosome formation (data not shown). The other MDD-linked variants (E777K, N782T) both occur in a 13 residue stretch connecting the 4th and 5th repeats of the first WD-repeat domain. The WD repeat regions appear to form two separate b propeller domains. 3 These are thought to have a regulatory role in monomeric Apaf-1, interacting with the hub region and thus locking Apaf-1 in a closed conformation that is not competent for oligomerization and procaspase 9 recruitment. The interaction of cytochrome c with the WD regions uncovers functional regions of Apaf-1. 3 These variants (E777K, N782T) are not located within a WD repeat, so it is unlikely that they disrupt the domain's b propeller tertiary structure. Instead this inter-repeat sequence may be important for either the intramolecular interaction with the CARD or CED-4 homology region (the hub region), or the intermolecular interaction with cytochrome c. It is possible that these variants affect either of these interactions, facilitating hub release or cytochrome c binding to promote apoptosome formation. In titration experiments, E777K and N782T do not show any differential dependence on cytochrome c concentration from wild-type Apaf-1 (data not shown). More detailed examination of the phenotypes of these MDD-linked variants (or the other variants reported herein) may lead to better mechanistic understanding of Apaf-1 function.
Our results have bearing on the role of increased apoptosis in the etiology of MDD. Both increases of central nervous system apoptosis and decreases of a complementary process, neurogenesis, have been associated with a depressive state. These observations have led to a neurotrophic hypothesis of MDD, that a deficiency in neurotrophic factors leads to hippocampal changes and disturbed neural plasticity. 7, 9 Pathological effects of stress in the hippocampus have been clearly demonstrated. Repeated or severe stress is associated with atrophy and death of CA3 pyramidal neurons 21 and reduced neurogenesis of dentate gyrus granule neurons in the hippocampus of adult animals. 22 Stress can also reduce the expression of neurotrophic factors in hippocampus (eg, brain-derived neurotrophic factor, BDNF), contributing to increased vulnerability of the affected neurons. 23 Clinical studies have demonstrated atrophy of the hippocampus and reduced number of neurons and glia in prefrontal cortex of depressed patients. 24, 25 BDNF and neurotrophin-3 are neurotrophic factors that have shown antidepressant-like effect in animal models of depression. 26, 27 Consistent with this hypothesis, antidepressant treatments increase BDNF expression 28 and neurogenesis in adult rat hippocampus. 29 Recently, a direct requirement of hippocampal neurogenesis for the animal behavioral effects of antidepressants was demonstrated. 10 Finally, treatment with the antidepressant tianeptine was observed to reduce apoptosis in both dentate gyrus and temporal cortex of both stressed and unstressed rats.
11 While these observations support association with cell death or survival, all are consistent with changes of apoptosis or neurogenesis as consequences of a depressive state. Our work strongly indicates a causative link of increased apoptosis to MDD in some patients. Thus we propose that alterations of cellular survival can be etiologic for, not merely symptomatic of, MDD.
An important question remaining is whether the functional expression of MDD-associated APAF1 variants occurs during ontogeny or is ongoing in adulthood. The answer will influence which new therapeutic approaches follow from the discovery of APAF1 as a depression gene and of a common gain-offunction phenotype for the alleles that cosegregate with MDD. For example, if the influence of Apaf-1 alleles as etiologic factors for MDD was important only during development, direct inhibition of neuronal apoptosis might not be expected to be an effective therapy. Volume reductions of the anterior cingulate cortex have been observed by magnetic resonance imaging in MDD patients. 25 Such reductions have been observed early in the illness, suggesting a developmental component, but may become more severe following the onset of MDD. 30 Hippocampal volume reductions have been observed in a subset of MDD patients, 24 but we are not aware that the temporal appearance of these changes has been established prior to or in the early stages of disease. These structural imaging results in MDD patients to date do not appear sufficient to clarify whether APAF1 variants are likely to have effects more in ontogeny than in adulthood.
Our work has important implications for future therapy and diagnosis of MDD. By establishing that altered cellular survival can lead to MDD, this study provides impetus to test molecules that inhibit neuronal apoptosis for their potential as new therapeutic classes of antidepressant drugs. Further, it may be possible to define more precise neurobiological phenotypes of MDD based on the characteristics of patients who express the gain-of-function Apaf-1 variant proteins. Through development of novel therapeutics and ability to diagnose MDD subtypes, our future hope is for more effective and individualized treatment of this common and devastating disease.
